Swedish reasearchers link up cancer surviv...Using a national supercomputer, Swedish researchers have analysed how protein expression of the 315 known cancer genes translates into cancer overall survival. more ➔
Metsä Group started up its bioproduct mil...Finnish Metsä Group has started its mill for bio-based products. The €1.2bn investments production capacity is 1.3 million tonnes of softwood pulp a year. more ➔
Oxford Immunotec value drops after public...UK-headquartered immunodiagnostics specialist Oxford Immunotec Global plc’s share value slipped by $1.31 to $16.02 after the company raised US-$40.125m on Monday in an public offering of 2.5 million … more ➔
Mundipharma pays US$250 for CAP7.1 German CellAct GmbH has cashed in US$250m (€212m) from Mundipharma in a licence deal for CAP7.1, a Phase II drug to treat the rare biliary tract cancer. more ➔
Sepsis: Adrenomed receives approval for PO...Germany is the first country that has granted full approval to Adrenomed to conduct a Phase II study with the monoclonal antibody adrecizumab in patients with early septic shock. Within the ADR-02 … more ➔
CDPQ acquires stake in SebiaCaisse de dépôt et placement du Québec (CDPQ) is set to acquire a minority stake in diagnostic electrophoresis player Sebia Group from private equity investors Astorg and Montagu. more ➔
Swiss Roivant bags US$1.1bn financingSerial drug licensee Roivant Sciences GmbH (Basel) has cashed in US$1.1bn (€937m) in an equity financing led by SoftBank Vision Fund and co-financed by existing investor Dexcel Pharma. more ➔
Voluntary health agency jump-starts Selvit... The Leukemia & Lymphoma Society (LLS) and Polish drug developer Selvita SA have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients … more ➔
LEO orders Hitgen to discover new leads In a multi-year collaboration with LEO Pharma A/S, Chinese Hitgen is poised to discover novel small molecule leads for multiple therapeutic targets chosen by the Danish skin treatment specialist. more ➔
Vernalis receives next veto by FDA British biotech company Vernalis has to deal with another Complete Response Letter by US authority FDA – this time regarding the New Drug Application for its cough and cold treatment CCP-08. more ➔
